Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Companies / Emalex Biosciences
Entity

Emalex Biosciences

Tracked across 1 events · 8 articles · First seen Apr 29, 2026 · Last active Jun 10, 2026

Sentiment
70
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Business
Teva acquires Emalex Biosciences for ecopipam
Sun Pharma announced the closing of its acquisition of Emalex Biosciences, a private company created by Paragon Biosciences. The acquisition, valued at $700 million upfront with potential for an additional $200 million in milestone payments…
Impact: Emalex Biosciences was acquired by Sun Pharma for $700 million upfront, with potential for additional milestone payments and royalties. This acquisition validates its work in developing Ecopipam for Tourette syndrome.
Jun 10, 2026 · 8 articles
Key Actions (2)
100 Sun Pharma closed acquisition Emalex BiosciencesTeva acquires Emalex...
80 Emalex Biosciences developed new treatmentsTeva acquires Emalex...
NEWSDESK
Track Emalex Biosciences live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.